I85PREP
⌘ K
CRNO study materials
CRNO study resources

CRNO practice questions

One question at a time. Build your CRNO understanding.

First 50 of 200 questions. Each one lists the choices, the correct answer, and an explanation. The checker at the top of this page saves progress in this browser when it is available.

Continue in the practice tool above to load more questions, 50 at a time.

Question 1Clinical Research Foundations and Regulatory Framework

Which document constitutes the legally binding international ethical framework specifically governing research involving human subjects that was adopted by the World Medical Association?

  1. The Belmont Report
  2. The Nuremberg Code
  3. The Declaration of Helsinki Correct answer.
  4. The ICH E6 Good Clinical Practice guideline

Explanation

The Declaration of Helsinki was adopted by the World Medical Association in 1964 and is the foundational international statement of ethical principles for medical research involving human participants. It is periodically revised and is often incorporated into national regulations. The other documents serve different roles or are not WMA instruments.

Question 2Clinical Research Foundations and Regulatory Framework

A sponsor is planning a multinational trial and wants a single harmonised standard for trial conduct accepted by regulators in the EU, Japan, and the United States. Which instrument should the trial be designed to comply with?

  1. The Declaration of Geneva
  2. ISO 14155
  3. 21 CFR Part 11
  4. ICH E6 Good Clinical Practice Correct answer.

Explanation

ICH E6 GCP is the harmonised tripartite guideline developed by regulators and industry from the EU, Japan, and the United States, and it is the reference standard for designing and conducting trials whose data are intended for submission to those authorities. It covers responsibilities of sponsors, investigators, and IRBs/IECs. The other instruments address devices, physician ethics, or electronic records only.

Question 3Clinical Research Foundations and Regulatory Framework

In the ICH E6 taxonomy of protocol deviations, which category specifically refers to deviations that may significantly affect the completeness, accuracy, or reliability of trial data or that may significantly affect a subject's rights, safety, or well-being?

  1. Important deviation Correct answer.
  2. Minor deviation
  3. Major deviation
  4. Protocol violation

Explanation

ICH E6(R2) distinguishes important deviations, which may significantly affect data reliability or subject rights, safety, and well-being, from minor ones. Important deviations must be documented and typically reported to the sponsor and IRB/IEC. The term 'protocol violation' is used in some regional guidance but is not the ICH E6 category.

Question 4Clinical Research Foundations and Regulatory Framework

A research site reports that a participant was enrolled despite a prohibited concomitant medication listed in the protocol. Under ICH E6, who is primarily responsible for documenting and explaining the deviation and for taking appropriate corrective action at the site?

  1. The institutional review board chair
  2. The contract research organization monitor
  3. The investigator Correct answer.
  4. The sponsor's data manager

Explanation

ICH E6 assigns the investigator responsibility for conducting the trial in accordance with the protocol and for documenting and explaining any deviations from it. The investigator must also implement corrective action and communicate with the sponsor and IRB/IEC as required. Other parties may oversee or verify, but the site-level accountability rests with the investigator.

Question 5Clinical Research Foundations and Regulatory Framework

Under the ICH E6 definition, which activity is part of 'source data' rather than an 'original record' transcription?

  1. A case report form entry transcribed from a nurse's handwritten note
  2. The first recording of a participant's blood pressure in the clinic's electronic health record Correct answer.
  3. A certified copy of a hospital chart made after the chart was destroyed
  4. A sponsor's derived analysis dataset

Explanation

Source data are all information in original records and certified copies of original records of clinical findings, observations, or other activities necessary for the reconstruction and evaluation of the trial. The first recording in the electronic health record is the original source. Transcriptions into CRFs and derived datasets are not source data.

Question 6Clinical Research Foundations and Regulatory Framework

A trial is being conducted in the EU under the Clinical Trials Regulation. Which body is responsible for the scientific and ethical assessment of the trial application through the Clinical Trials Information System?

  1. The reporting Member State and concerned Member States Correct answer.
  2. The European Medicines Agency Committee for Medicinal Products for Human Use
  3. The sponsor's independent data monitoring committee
  4. The European Commission's pharmacovigilance risk assessment committee

Explanation

Under Regulation (EU) 536/2014, the reporting Member State performs the initial assessment and concerned Member States review the application within the Clinical Trials Information System, covering scientific and ethical aspects. The EMA committees handle marketing authorisation and pharmacovigilance, not individual trial authorisation.

Question 7Clinical Research Foundations and Regulatory Framework

Which element is required in an informed consent document under ICH E6 but is often overlooked because it concerns finances rather than medical risk?

  1. An explanation of whom to contact for answers about the trial
  2. A statement that participation is voluntary and refusal is possible
  3. A statement that the trial involves research and the expected duration of participation
  4. A description of the anticipated prorated payment, if any, to the subject for participating Correct answer.

Explanation

ICH E6 requires the consent document to describe anticipated prorated payment, if any, to the subject for participating in the trial. Payment information is a distinct required element separate from contact details, voluntariness, and the research description. All four listed items are required elements, but only one addresses compensation.

Question 8Clinical Research Foundations and Regulatory Framework

A participant in a phase 2 oncology trial wishes to withdraw consent entirely. Under ICH E6, which statement best describes the investigator's obligation regarding data already collected?

  1. The investigator should retain and use data collected up to withdrawal while clarifying in the consent discussion what will happen to the data Correct answer.
  2. All data collected from that participant must be deleted from the trial database upon request
  3. The sponsor decides unilaterally whether the participant's data may be retained
  4. The investigator must continue collecting follow-up safety data regardless of the participant's wishes

Explanation

ICH E6 states that although a subject is not obliged to give a reason for withdrawing, the investigator should attempt to ascertain it while fully respecting the subject's rights. Data collected before withdrawal generally remain usable, and the consent discussion should explain this. Continued data collection requires the participant's agreement.

Question 9Clinical Research Foundations and Regulatory Framework

In the Common Rule (45 CFR 46), which category of research is exempt from the requirement for continuing review by an IRB after initial approval?

  1. Research that involves no more than minimal risk and meets an exempt category Correct answer.
  2. Research involving prisoners as subjects
  3. Any research conducted at a site outside the United States
  4. Research using an unapproved investigational drug

Explanation

The revised Common Rule eliminated the requirement for continuing review for research that is determined to be exempt or that involves no more than minimal risk and meets specified criteria. Prisoner research and FDA-regulated drug studies remain subject to stricter oversight. Exemption status is determined based on the research activities, not geography.

Question 10Clinical Research Foundations and Regulatory Framework

Which principle from the Belmont Report requires that the burdens and benefits of research be distributed fairly across populations, and that the selection of subjects be equitable?

  1. Integrity
  2. Justice Correct answer.
  3. Respect for persons
  4. Beneficence

Explanation

The Belmont Report's principle of justice concerns the fair distribution of research burdens and benefits and requires equitable subject selection. Respect for persons addresses autonomy and informed consent, while beneficence addresses risk-benefit assessment. Integrity is a GCP principle, not one of the three Belmont principles.

Question 11Clinical Research Foundations and Regulatory Framework

A sponsor wants to add a new exploratory biomarker substudy to an ongoing trial. Which action is required before the substudy can begin at participating sites?

  1. Amend the protocol and obtain approval from the IRB/IEC and, where required, regulatory authorities before implementation Correct answer.
  2. Notify the IRB/IEC by letter after the substudy has started
  3. Obtain only the sponsor's medical monitor's written approval
  4. Register the substudy on a public registry before the first participant is enrolled

Explanation

ICH E6 requires that the sponsor obtain agreement from the investigator and documented approval from the IRB/IEC and, where applicable, regulatory authorities before implementing a protocol amendment that affects subject safety or trial conduct. Retrospective notification is not acceptable for substantive changes. Registration alone does not substitute for approval.

Question 12Clinical Research Foundations and Regulatory Framework

In the ICH E6 framework, which party holds ultimate responsibility for the quality and integrity of the trial data and for selecting qualified investigators?

  1. The clinical research associate
  2. The sponsor Correct answer.
  3. The IRB/IEC
  4. The principal investigator

Explanation

ICH E6 assigns the sponsor responsibility for implementing and maintaining quality assurance and quality control systems to ensure the trial is conducted and data are generated, documented, and reported in compliance with the protocol, GCP, and applicable regulations. The sponsor also selects qualified investigators and ensures adequate resources. Investigators, IRBs, and monitors have defined but narrower roles.

Question 13Clinical Research Foundations and Regulatory Framework

A monitor identifies that a site's temperature logs for investigational product storage are missing for two weeks. Which immediate action is most consistent with ICH E6 monitoring responsibilities?

  1. Immediately discontinue the site's participation in the trial
  2. Document the finding, assess the impact on product integrity and subject safety, and report it to the sponsor for follow-up Correct answer.
  3. Adjust the temperature logs retrospectively using ambient room readings
  4. Wait until the next scheduled monitoring visit to raise the issue

Explanation

ICH E6 requires monitors to follow the sponsor's written SOPs and to report findings and deviations to the sponsor. Missing storage documentation must be documented and its impact on product integrity and participant safety assessed, with corrective action agreed. Retrospective reconstruction or unilateral site termination exceeds the monitor's role.

Question 14Clinical Research Foundations and Regulatory Framework

Which statement correctly describes the relationship between the Declaration of Helsinki and the ICH E6 Good Clinical Practice guideline?

  1. The Declaration of Helsinki is an ethical statement, while ICH E6 provides operational standards for trial conduct that incorporate its ethical principles Correct answer.
  2. ICH E6 applies only to pharmaceutical industry sponsors
  3. The Declaration of Helsinki applies only to investigator-initiated trials
  4. ICH E6 supersedes the Declaration of Helsinki in all jurisdictions

Explanation

The Declaration of Helsinki articulates ethical principles for research with human participants, while ICH E6 translates those principles into operational standards for the design, conduct, recording, and reporting of trials. ICH E6 explicitly references the Declaration of Helsinki as an ethical foundation. Neither instrument is limited by trial type or sponsor type in the way the other options suggest.

Question 15Clinical Research Foundations and Regulatory Framework

A sponsor plans to use an electronic data capture system for a pivotal trial. Which requirement under 21 CFR Part 11 applies to the audit trail?

  1. Audit trails need only capture changes made by the sponsor's staff
  2. Audit trails must be computer-generated, time-stamped, and retained for the record retention period Correct answer.
  3. Audit trails may be disabled if the sponsor's SOP permits it
  4. Audit trails must be printed and signed in ink daily

Explanation

21 CFR Part 11 requires that secure, computer-generated, time-stamped audit trails independently record the date and time of operator entries and actions that create, modify, or delete electronic records. The audit trail must be retained for at least as long as the underlying records. Disabling audit trails or limiting them to certain staff defeats the requirement.

Question 16Clinical Research Foundations and Regulatory Framework

Which situation most clearly meets the ICH E6 definition of a serious adverse event?

  1. A transient elevation in liver enzymes noted on routine blood work
  2. A hospitalisation for observation following a fall at home unrelated to the trial
  3. A grade 2 headache that resolves with paracetamol within two hours
  4. A life-threatening anaphylactic reaction requiring emergency resuscitation Correct answer.

Explanation

A serious adverse event is any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability, or is a congenital anomaly. A life-threatening anaphylactic reaction meets the criterion directly. The other events do not meet seriousness criteria.

Question 17Clinical Research Foundations and Regulatory Framework

Under ICH E2A, which term describes an adverse event that is not serious but leads to discontinuation of the investigational product?

  1. Serious unexpected suspected adverse reaction
  2. Non-serious adverse event leading to discontinuation Correct answer.
  3. Adverse event of special interest
  4. Serious adverse event

Explanation

ICH E2A distinguishes serious from non-serious adverse events; an event that leads to discontinuation but does not meet seriousness criteria remains a non-serious adverse event, though it is important for safety evaluation. Adverse events of special interest are protocol-defined events requiring enhanced monitoring, not a seriousness category.

Question 18Clinical Research Foundations and Regulatory Framework

Which statement best describes the role of an independent data monitoring committee in a blinded trial?

  1. The IDMC reviews unblinded comparative safety and efficacy data and recommends whether the trial should continue, be modified, or be stopped Correct answer.
  2. The IDMC is responsible for obtaining informed consent from participants
  3. The IDMC replaces the IRB/IEC in reviewing protocol amendments
  4. The IDMC unblinds all participants at each scheduled meeting

Explanation

An IDMC is an independent group that reviews unblinded interim data to advise the sponsor on trial continuation, modification, or termination based on safety and efficacy. It does not unblind participants or replace the IRB/IEC, and consent remains the investigator's responsibility.

Question 19Clinical Research Foundations and Regulatory Framework

A sponsor's clinical trial application in the EU is submitted through CTIS. Under Regulation (EU) 536/2014, what is the maximum period for the reporting Member State's initial assessment of a standard application, excluding clock-stops for sponsor responses?

  1. 45 days
  2. 10 days
  3. 26 days Correct answer.
  4. 60 days

Explanation

Under Regulation (EU) 536/2014, the reporting Member State has 26 days for the initial assessment of a standard application, with possible clock-stops for further information from the sponsor. A 45-day period applies to the assessment of Part II in certain circumstances, and other timelines apply to substantial modifications.

Question 20Clinical Research Foundations and Regulatory Framework

Which document, prepared before trial initiation, describes the rationale and design of a trial in sufficient detail to justify the study and is a required component of the investigator's brochure or protocol?

  1. The investigational medicinal product dossier
  2. The statistical analysis plan
  3. The trial protocol Correct answer.
  4. The clinical study report

Explanation

The protocol is the document that describes the objective, design, methodology, statistical considerations, and organisation of a trial, and it justifies the study design. The clinical study report is written after the trial, the IMPD supports the quality and non-clinical data package, and the SAP details statistical methods.

Question 21Clinical Research Foundations and Regulatory Framework

An investigator at a site has a financial interest in the sponsor company. Under ICH E6 and applicable transparency rules, what is the appropriate handling of this interest?

  1. The interest should be disclosed only in the final clinical study report
  2. The investigator should resign from the trial only if the interest exceeds 10 percent of the company's shares
  3. The investigator should disclose the interest to the sponsor, the IRB/IEC, and where required the regulatory authority, and the interest should be managed to avoid undue influence Correct answer.
  4. The interest may be kept confidential if the investigator considers it immaterial

Explanation

ICH E6 requires investigators to disclose financial interests to the sponsor and IRB/IEC, and applicable transparency rules require disclosure of certain interests. These interests must be managed so they do not compromise trial integrity or participant safety. Confidentiality or post hoc disclosure does not satisfy the requirement.

Question 22Clinical Research Foundations and Regulatory Framework

Which statement accurately describes the relationship between the investigator's brochure and the protocol regarding reference safety information for expectedness assessment?

  1. The protocol always supersedes the investigator's brochure for expectedness assessment
  2. The investigator's brochure is never used for expectedness assessment
  3. The investigator's brochure, or the product information where permitted, provides the reference safety information used to assess whether a serious adverse reaction is expected Correct answer.
  4. Expectedness is determined solely by the sponsor's medical judgment without reference documents

Explanation

Expectedness of a serious adverse reaction is assessed against the reference safety information, which is typically contained in the investigator's brochure for an unapproved product or in the product information for an authorised one. The protocol may contain safety information but is not the standard reference for expectedness.

Question 23Clinical Research Foundations and Regulatory Framework

A site's IRB approval expires while participants are still in follow-up. What must the investigator do to continue the follow-up activities?

  1. Submit a continuing review or renewal application and obtain approval before the expiration date to continue activities requiring IRB oversight Correct answer.
  2. Stop all trial activities permanently and withdraw all participants
  3. Ask the sponsor to grant an extension on the IRB's behalf
  4. Continue follow-up because it is not interventional research

Explanation

Continuing review or renewal must be obtained before the approval expiration if activities requiring IRB oversight are to continue. Lapse of approval generally means no further research activities may proceed until approval is reinstated, except as necessary to protect participants' safety. The sponsor cannot extend IRB approval.

Question 24Clinical Research Foundations and Regulatory Framework

Which of the following best describes the purpose of the trial master file under ICH E6?

  1. It replaces the need for source documents at the site
  2. It contains only the final statistical analysis outputs
  3. It is maintained solely by the IRB/IEC
  4. It provides a documented record demonstrating the conduct of the trial and the quality of the data produced Correct answer.

Explanation

The trial master file is the sponsor's and investigator's collection of essential documents that individually and collectively permit evaluation of the conduct of a trial and the quality of the data produced. It does not replace source documents, and it is maintained by the sponsor and investigator, not the IRB.

Question 25Clinical Research Foundations and Regulatory Framework

A sponsor learns that a serious adverse reaction occurred at a site and that the event was not reported to the sponsor within the protocol-specified timeframe. Which action is most appropriate under ICH E6 and E2A?

  1. Remove the event from the safety database to avoid regulatory scrutiny
  2. Document the late reporting as a deviation, assess its impact, and implement corrective and preventive actions Correct answer.
  3. Take no action because the event was eventually reported
  4. Report the late reporting only if the event was fatal

Explanation

Late reporting of a serious adverse reaction is a deviation from the protocol and applicable safety reporting requirements. It should be documented, its impact assessed, and corrective and preventive actions implemented to prevent recurrence. Removing data or limiting reporting to fatal events is inappropriate.

Question 26Clinical Research Foundations and Regulatory Framework

Under the ICH E6 Good Clinical Practice guideline, which document must be approved by an Institutional Review Board or Independent Ethics Committee before a clinical trial may begin at a site?

  1. The trial master file
  2. The statistical analysis plan
  3. The protocol and informed consent form Correct answer.
  4. The clinical study report

Explanation

ICH E6 requires that the protocol, informed consent form, and any other written information provided to participants receive IRB/IEC approval before trial initiation. The clinical study report, statistical analysis plan, and trial master file are not submitted for prospective IRB/IEC approval in the same way.

Question 27Clinical Research Foundations and Regulatory Framework

A sponsor is designing a phase 3 trial and wants to ensure that the study is conducted in accordance with the Declaration of Helsinki. Which statement best describes the Declaration's role in relation to ICH E6?

  1. ICH E6 incorporates the ethical principles of the Declaration of Helsinki and provides more detailed operational guidance for trials. Correct answer.
  2. ICH E6 and the Declaration of Helsinki are mutually exclusive; compliance with one automatically ensures compliance with the other.
  3. The Declaration of Helsinki applies only to investigator-initiated trials, whereas ICH E6 applies to industry-sponsored trials.
  4. The Declaration of Helsinki is a legally binding treaty that supersedes ICH E6 in all signatory countries.

Explanation

The Declaration of Helsinki is a foundational ethical statement developed by the World Medical Association, and ICH E6 explicitly states that clinical trials should be conducted in accordance with its principles. ICH E6 then adds detailed requirements for sponsor and investigator responsibilities, making it more operationally specific than the Declaration alone.

Question 28Clinical Research Foundations and Regulatory Framework

A clinical trial is being conducted in the European Union under Regulation (EU) 536/2014. Which statement accurately describes the timeline for the initial assessment of a clinical trial application submitted through the Clinical Trials Information System (CTIS)?

  1. The reporting Member State has 60 days to assess the application, with no possibility of extension.
  2. The reporting Member State has 45 days to assess the application, with a possible extension of 31 days for trials involving advanced therapy investigational medicinal products. Correct answer.
  3. The reporting Member State has 30 days to assess the application, with a possible extension of 15 days for any trial.
  4. The reporting Member State has 90 days to assess the application, with a possible extension of 45 days for trials involving gene therapy.

Explanation

Under Regulation (EU) 536/2014, the reporting Member State has 45 days for the initial assessment of a clinical trial application, and this period can be extended by 31 days for trials involving advanced therapy investigational medicinal products. The other timelines do not reflect the regulation's provisions.

Question 29Clinical Research Foundations and Regulatory Framework

An investigator at a site has a financial interest in the sponsor company. Under ICH E6 and applicable transparency rules, which action is most appropriate?

  1. The investigator should disclose the financial interest to the IRB/IEC and the sponsor, and the disclosure should be managed according to institutional and regulatory requirements. Correct answer.
  2. The investigator should keep the financial interest confidential to protect participant trust.
  3. The investigator should resign from the trial to avoid any conflict of interest.
  4. The investigator should transfer all trial responsibilities to a sub-investigator without informing the sponsor.

Explanation

ICH E6 requires investigators to disclose financial interests to the sponsor and the IRB/IEC, and institutions must manage such conflicts. Transparency rules also mandate disclosure of certain financial arrangements. Simply resigning or hiding the interest is not the required approach.

Question 30Clinical Research Foundations and Regulatory Framework

Which principle from the Belmont Report requires that the burdens and benefits of research be distributed fairly across the population of potential participants?

  1. Justice Correct answer.
  2. Informed consent
  3. Beneficence
  4. Respect for persons

Explanation

The Belmont Report's principle of justice addresses the fair distribution of the burdens and benefits of research, ensuring that no group is unfairly burdened or denied benefits. Respect for persons concerns autonomy and protection of those with diminished autonomy, while beneficence concerns minimizing harm and maximizing benefit.

Question 31Study Design and Protocol Development

In a clinical research protocol, which section defines the specific research question, the population to be studied, and the endpoints to be measured?

  1. The investigator brochure summary
  2. The statistical analysis plan appendix
  3. The informed consent form appendix
  4. The objectives and endpoints section Correct answer.

Explanation

The objectives and endpoints section states the precise research question and the measurable outcomes that will answer it, including the population of interest. These elements anchor every downstream design decision, from sample size to analysis strategy.

Question 32Study Design and Protocol Development

A sponsor is designing a trial for a chronic condition where the primary interest is whether a new therapy is superior to placebo under tightly controlled conditions. Which design element most directly supports internal validity in this scenario?

  1. Increasing the number of participating countries
  2. Adding patient-reported satisfaction surveys as co-primary endpoints
  3. Randomization with allocation concealment Correct answer.
  4. Broadening eligibility criteria to include all comers

Explanation

Randomization with allocation concealment prevents selection bias and balances known and unknown confounders between arms, which is central to internal validity. Broader eligibility or geographic expansion affects generalizability rather than internal validity.

Question 33Study Design and Protocol Development

Which statement best describes the purpose of a comparator arm in a randomized controlled trial?

  1. It eliminates the need for a statistical analysis plan.
  2. It replaces the requirement for informed consent.
  3. It guarantees that every participant receives an active treatment.
  4. It provides a reference against which the effect of the investigational intervention is measured. Correct answer.

Explanation

A comparator arm supplies the benchmark against which the investigational intervention's effect is estimated, whether the comparator is placebo or an active standard of care. Without a valid comparator, the observed outcome cannot be attributed to the intervention.

Question 34Study Design and Protocol Development

A protocol specifies that the primary endpoint will be analyzed in the intention-to-treat population. What does this principle require?

  1. Participants are analyzed according to the treatment they actually received.
  2. Only participants with no protocol deviations are analyzed.
  3. Only participants who completed the full treatment course are analyzed.
  4. All randomized participants are analyzed according to their assigned group. Correct answer.

Explanation

Intention-to-treat analysis includes all randomized participants and attributes them to the group to which they were assigned, regardless of adherence or deviations. This preserves the benefits of randomization and avoids bias from selective exclusion.

Question 35Study Design and Protocol Development

During protocol development, a team must define how participants will be assigned to treatment groups to minimize predictability of the next assignment. Which approach best achieves this?

  1. Central randomization with concealed allocation sequences Correct answer.
  2. Assignment by the treating investigator's clinical judgment
  3. Alternating assignment by enrollment order
  4. Sequential enrollment with open assignment lists posted at each site

Explanation

Central randomization with concealed sequences prevents investigators from predicting or influencing upcoming assignments, protecting against selection bias. Predictable schemes such as alternation or open lists undermine the purpose of randomization.

Question 36Study Design and Protocol Development

Which element of a protocol most directly specifies the schedule of study visits, assessments, and procedures?

  1. The publication policy statement
  2. The data management plan appendix
  3. The background and rationale section
  4. The schedule of activities table Correct answer.

Explanation

The schedule of activities, often presented as a table, maps each visit to the assessments and procedures performed at that time point. It operationalizes the protocol's objectives into a concrete timeline for sites.

Question 37Study Design and Protocol Development

A protocol team is choosing between a parallel-group and a crossover design for a stable chronic disease with a rapidly reversible treatment effect. Which consideration most favors a crossover design?

  1. It allows different participants to receive different sequences without randomization.
  2. It removes the need for a washout period between treatment periods.
  3. It eliminates the possibility of carryover effects.
  4. Each participant serves as their own control, reducing between-subject variability. Correct answer.

Explanation

In a crossover design each participant receives multiple treatments, so within-subject comparisons reduce the influence of between-subject variability and can increase efficiency. This advantage depends on a stable condition and adequate washout to limit carryover.

Question 38Study Design and Protocol Development

Which document element typically describes the rationale for the chosen sample size in a protocol?

  1. The monitoring plan appendix
  2. The statistical considerations section Correct answer.
  3. The ethics committee roster
  4. The investigational product labeling

Explanation

The statistical considerations section presents the assumptions, effect size, variability, power, and alpha used to justify the planned sample size. This allows reviewers to assess whether the trial is adequately powered for its objectives.

Question 39Study Design and Protocol Development

A protocol includes a stopping rule for futility at an interim analysis. What is the primary purpose of such a rule?

  1. To discontinue the trial early when accumulating data suggest the intervention is unlikely to demonstrate benefit Correct answer.
  2. To permit selective reporting of favorable interim results
  3. To guarantee that the trial will reach its planned sample size
  4. To allow investigators to modify the primary endpoint after enrollment begins

Explanation

Futility stopping rules allow a trial to end early when interim data indicate a low likelihood of demonstrating the hypothesized benefit, conserving resources and limiting exposure. They are pre-specified to protect trial integrity and control error.

Question 40Study Design and Protocol Development

Which criterion best distinguishes a confirmatory trial from an exploratory trial in a development program?

  1. Use of a single study site rather than multiple sites
  2. Absence of a written protocol
  3. A pre-specified hypothesis tested with a controlled type I error rate to support a regulatory claim Correct answer.
  4. Enrollment of fewer than one hundred participants

Explanation

Confirmatory trials test pre-specified hypotheses under rigorous control of type I error to support regulatory or labeling claims. Exploratory trials are more flexible and hypothesis-generating rather than definitive.

Question 41Study Design and Protocol Development

A protocol defines the primary endpoint as change from baseline in a symptom score at week 24. Which statement about endpoint selection is most accurate?

  1. Primary endpoints should always be surrogate laboratory markers rather than clinical outcomes.
  2. The primary endpoint should be pre-specified and directly reflect the trial's primary objective. Correct answer.
  3. The primary endpoint must be identical across all trials in a therapeutic area.
  4. Any endpoint measured during the trial may be designated primary after unblinding.

Explanation

The primary endpoint must be defined before the trial begins and must answer the primary objective, because it drives sample size, analysis, and interpretation. Post hoc designation of a primary endpoint undermines validity.

Question 42Study Design and Protocol Development

Which protocol element describes the procedures used to verify that reported trial data are accurate and complete?

  1. The data management and monitoring provisions Correct answer.
  2. The appendix containing abbreviations
  3. The references list
  4. The introduction section

Explanation

Data management and monitoring provisions describe source data verification, query resolution, and oversight activities that ensure data quality. These procedures support the reliability of trial results and regulatory compliance.

Question 43Study Design and Protocol Development

A protocol includes both inclusion and exclusion criteria. Which statement best explains the role of exclusion criteria?

  1. They remove individuals whose characteristics could confound results or increase risk. Correct answer.
  2. They define the target population that the trial intends to generalize to.
  3. They determine the randomization sequence for enrolled participants.
  4. They replace the need for informed consent documentation.

Explanation

Exclusion criteria identify characteristics that make potential participants unsuitable, such as safety risks, confounding conditions, or inability to comply. Inclusion criteria define the target population, while exclusion criteria refine it for safety and validity.

Question 44Study Design and Protocol Development

When a protocol specifies a washout period before randomization, what is the main reason for including it?

  1. To allow prior medications or effects to clear so baseline measurements reflect the participant's untreated state Correct answer.
  2. To permit the sponsor to change the eligibility criteria mid-trial
  3. To lengthen the trial and increase the total number of visits
  4. To ensure that all participants receive the investigational product before randomization

Explanation

A washout period allows residual effects of prior treatments to dissipate so that baseline and subsequent measurements are not confounded. This improves the interpretability of treatment effects.

Question 45Study Design and Protocol Development

A sponsor plans to use a blinded design but is concerned about emergency unblinding at sites. Which protocol provision best addresses this concern?

  1. Removing the requirement to record unblinding events
  2. Allowing any site staff member to unblind at their discretion
  3. Pre-specified procedures describing when and how unblinding may occur, with documentation Correct answer.
  4. Eliminating the blinding altogether to avoid complexity

Explanation

Protocols should specify emergency unblinding procedures, who may authorize unblinding, and how events are documented, preserving trial integrity while protecting participant safety. Uncontrolled or undocumented unblinding threatens validity.

Question 46Study Design and Protocol Development

Which statement best describes the role of a protocol amendment?

  1. It formally documents changes to an approved protocol, with justification and required approvals. Correct answer.
  2. It is used only to correct typographical errors after study completion.
  3. It replaces the need for ethics committee review of the study.
  4. It allows investigators to deviate from the protocol without documentation.

Explanation

A protocol amendment is a formal, justified modification to an approved protocol that must be reviewed and approved as required before implementation. This preserves regulatory and ethical oversight of the study.

Question 47Study Design and Protocol Development

A trial team must decide whether to use a run-in period before randomization. Which scenario most supports including a placebo run-in?

  1. The team wants to ensure that all participants receive active drug
  2. The team wants to increase the number of adverse events observed
  3. The team wants to eliminate the need for a control arm
  4. The team wants to identify and exclude participants who are unlikely to adhere or who respond strongly to placebo before randomization Correct answer.

Explanation

A placebo run-in can identify non-adherent participants or strong placebo responders and exclude them before randomization, potentially improving assay sensitivity. It must be balanced against reduced generalizability.

Question 48Study Design and Protocol Development

Which protocol section typically describes how adverse events and serious adverse events will be collected, assessed, and reported?

  1. The site feasibility questionnaire
  2. The statistical analysis plan appendix
  3. The informed consent form
  4. The safety reporting section Correct answer.

Explanation

The safety reporting section defines adverse event definitions, seriousness criteria, assessment of causality and severity, and reporting timelines. Clear specifications ensure consistent safety oversight across sites.

Question 49Study Design and Protocol Development

A protocol specifies an adaptive design with a pre-planned sample size re-estimation. Which principle is most important to preserve trial validity?

  1. The adaptation may be designed after the interim data are reviewed.
  2. The adaptation rule and its decision criteria must be pre-specified before data are examined. Correct answer.
  3. The adaptation should remain confidential from regulators and ethics committees.
  4. The adaptation should be applied only to the control arm.

Explanation

Adaptive designs require pre-specification of adaptation rules to control type I error and prevent bias from data-driven decision making. Transparency with regulators and ethics committees supports acceptability.

Question 50Study Design and Protocol Development

Which statement best describes the function of a Data Monitoring Committee in a clinical trial?

  1. It performs source data verification during monitoring visits.
  2. It enrolls participants and obtains informed consent at each site.
  3. It independently reviews accumulating safety and efficacy data and recommends whether the trial should continue. Correct answer.
  4. It writes the statistical analysis plan without sponsor input.

Explanation

A Data Monitoring Committee provides independent oversight of interim safety and efficacy data and can recommend continuation, modification, or termination. Its independence protects participants and trial integrity.